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Abstract. The purpose of this study was to develop predic-
tive/prognostic markers for liver metastasis and recurrence 
following liver resection, investigating not only clinical 
parameters but also molecular markers that are known to be 
involved in the process of liver metastasis. Seventy colon 
cancer patients with either no distant metastasis (group A) or 
with resectable synchronous liver metastasis only (group B) 
were prospectively enrolled. All 70 patients received curative 
resection of the primary tumor. Group B patients underwent 
additional liver resection. Clinical parameters as well as serum 
levels of molecular markers [carcinoembryonic antigen (CEA), 
osteopontin, matrix metalloproteinase-7 (MMP-7), tissue 
inhibitor of metalloproteinase-1 (TIMP-1), hepatocyte growth 
factor (HGF), vascular endothelial growth factor (VEGF) and 
E-selectin] from both tumor drainage (DV) and peripheral 
veins (PV) were analyzed. Results showed the clinical param-
eters were not significantly different between groups A and B. 
Nonetheless, the levels of VEGF and TIMP-1 from both DV 
and PV were significantly higher in group B compared to 
group A. In group A, 10 out of 33 (27.0%) patients developed 
metachronous liver metastasis. High levels of VEGF and 
TIMP-1 from DV were found to be significantly correlated 
with metachronous liver metastasis. In group B, 20 out of 33 
(60.6%) patients had intrahepatic recurrence following resec-
tion of synchronous liver metastasis. The levels of VEGF from 
DV and the levels of TIMP-1 both from PV and DV were 
found to be significantly correlated with intrahepatic recur-
rence. Forty patients (7 from group A and 33 from group B) 
had liver resection and their 5-year disease-free survival rate 
was 15.9%. Univariate and multivariate analyses of prognostic 
factors revealed that the levels of VEGF and TIMP-1 from 
DV as well as the presence of lymph node metastasis from 
the primary tumor, synchronous metastasis and R1 resection 
were significantly associated with worse prognosis. The colon 
cancer patients with high levels of VEGF and TIMP-1 detected 
from the DV at the time of their initial surgery were found to 
have a high risk of metachronous liver metastasis and hepatic 
recurrence following the resection of synchronous liver metas-
tasis. The high levels of VEGF and TIMP-1 were found to be 
significant predictive factors for poor prognosis following 
liver resection. These results require validation but pave the 
way for future transitional or clinical studies that may provide 
a greater understanding of colon cancer liver metastasis.
Introduction
Liver metastasis occurs in almost 50% of patients with colon 
cancer during the course of the disease (1). Confined liver 
metastasis from colon cancer may be successfully treated 
by surgical resection with a 5-year survival ranging from 
20 to 40% (2). However, of those patients who undergo surgical 
resection for liver metastasis, more than two thirds experience 
recurrence (3-5). Therefore, liver metastasis is a crucial issue 
for the treatment of colon cancer and it would be invaluable 
to develop predictive markers for screening high risk groups 
of patients for liver metastasis and prognostic markers for 
recurrence following liver resection. Although numerous 
studies have reported prognostic factors for recurrence and 
survival following hepatectomy and predicive factors for liver 
metastasis our current knowledge remains incomplete. Many 
studies regarding this issue have been carried out. However, 
the majority of previous studies investigated only clinical 
parameters. Recent studies in search of prognostic factors for 
cancer have involved molecular markers that are known to 
be associated with the mechanism of the disease (6,7). Thus, 
investigating the molecular markers that are correlated with 
colon cancer liver metastasis may improve our understanding 
of its prognosis. Currently, a limited number of studies are 
available that cover not only clinical parameters but also 
molecular markers.
The purpose of this study was to develop predictive/prog-
nostic markers for liver metastasis and recurrence following 
liver resection, investigating not only clinical parameters but 
also molecular markers that are known to be involved in the 
process of liver metastasis.
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Materials and methods
Patients, treatment and follow-up protocol. We prospectively 
enrolled 70 colon cancer patients who underwent surgery 
between August 2004 and June 2006. The eligibility criteria 
included age between 20 and 70 years, biopsy proven adeno-
carcinoma arising from the colon or rectum, radiologically 
confirmed M0 or with resectable synchronous liver metastasis 
(M1). Exclusion criteria were: patients with unresectable 
liver metastasis or extrahepatic metastasis, history of cancer 
within five years, poor medical condition that disallowed 
surgery or chemotherapy, and pregnancy. Resectability was 
determined by the Colorectal Tumor Board at Severance 
Hospital, Yonsei University Health System, Seoul, Korea, 
which is composed of surgical and medical oncologists as 
well as radiologists and pathologists. Abdominal computed 
tomography (CT) scans and/or positron emission tomography 
(PET) ruled out extrahepatic metastasis. Enrolled patients 
were classified into two groups: group A comprised patients 
without liver metastasis and group B comprised patients with 
synchronous liver metastasis.
The patients received neither chemotherapy nor radiation 
therapy prior to surgery. The patients in group A received 
curative surgery for the primary tumor (i.e., colon cancer) 
only and postoperative adjuvant chemotherapy was admin-
istered on the basis of their pathological reports. In group B, 
the patients received surgery for the primary tumor plus liver 
resection with curative intent and all were recommended 
to receive postoperative chemotherapy. The regimen was 
decided by the treating physician. Postoperative follow-up 
was carried out every three months. Radiological evaluation 
with CT and/or PET-CT was carried out every six months to 
detect any recurrence.
The study was approved by the Institutional Review Board, 
and informed consent was obtained either from the patient or 
the patient's family.
Selection of candidate molecules. To determine potential 
candidate molecules for this study, we searched the medical 
database PubMed using the keywords: colon neoplasms, liver 
metastasis and biological markers. We limited our search scope 
to studies involving adults above the age of 19 and human 
subjects only. We only included English language publications. 
Following retrieval of the list of publications we limited our 
focus to molecules that could be detected in the blood and that 
could be analyzed by enzyme-linked immune specific assay 
(ELISA) with commercially available antibodies. We then 
reviewed the body of relevant studies published and selected 
the seven molecules that were most widely studied and were 
known to be involved in each step of the liver metastatic 
process (Table I).
Table I. Selected molecular markers: previous study results and the suggested relationship with colon cancer liver metastasis.
Molecule Previous study results and suggested mechanism (Refs.)
MMP-7 (matrilysin) Overexpressed in liver metastasis (13,14); degrades basement membrane
 and activates gelatinases (15,16)
TIMP-1 Higher serum level in patients with liver metastasis (10,11); growth stimulation and
 inhibition of apoptosis (17)
E-selectin Overexpressed in patients with metastasis (18,19); anchoring to target organs (20,21)
CEA Stimulates Kupffer cells to enhance cancer cell adhesion (22)
Osteopontin Correlates with cancer progression, silencing suppresses metastasis (23,24)
VEGF Correlates with cancer progression (8,25)
HGF Correlates with cancer progression (9,17)
CEA, carcinoembryonic antigen; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor.
Table II. Patient characteristics.
Clinical variables Group A Group B P
 (n=37) (n=33)
Mean age (years) 56.5±10.0 58.8±10.2 0.903
Male-to-female ratio 19:18 21:12 0.300
pT
  pT2   1   0 >0.999
  pT3-pT4 36 33 
pN
  pN0 12 10 0.544
  pN1   9   5 
  pN2 16 18 
Location
  Right colon   6   5 0.903
  Left colon/rectum 31 28 
Histology
  Well/mod. diff. 30 26 0.811
  Poorly/mucinous   7   7 
Lymphovascular invasion   2 11 0.004
Right colon was defined as from the appendix and cecum to the 
proximal 2/3 of transverse colon. Left colon from the distal 1/3 of the 
transverse colon to the rectum. mod. diff., moderately differentiated.
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Blood sampling and ELISA. Blood samples (5 ml) were drawn 
from the peripheral vein (PV) and tumor drainage vein (DV) 
and placed in plain tubes. PV blood was obtained 1 h prior to 
surgical incision. DV blood was obtained prior to the ligation 
of any branch of the superior mesenteric vein  in patients with 
proximal colon cancer and prior to the ligation of the inferior 
mesenteric vein in patients with distal colon and rectal cancer. 
Samples were immediately centrifuged and plasma and serum 
were separately stored at -70˚C until analysis. ELISA for all 
seven molecules was performed using commercially available 
kits according to the manufacturer's instructions (VEGF, HGF, 
E-selectin, MMP-7, TIMP-1, osteopontin: R&D Systems, Inc., 
MN, USA; CEA: IBL-Hamburg GmbH, Hamburg, Germany). 
Diluted serum was transferred to wells of plates pre-coated 
with primary antibody. Following the recommended incuba-
tion period, plates were washed with buffer solution, and 
substrate solution was added and incubated as instructed. The 
wells were developed with color-reagent. Stop solution was 
added to each well after incubation and the optical density was 
measured at a wavelength of 450 nm using automated optical 
densitometry. Each sample was run in triplicate, and the mean 
value was used for analysis. If the R2 of standard solutions was 
<0.98, data from the plate were excluded.
Statistical analysis. Analyzed clinical parameters included 
age, gender, the location of the tumor (right versus left colon), 
TNM stage, histological grade and lymphovascular invasion. 
Data on molecular factor levels are shown as the mean ± stan-
dard deviation (SD). The Mann-Whitney U-test, Fisher's exact 
test and McNemar test were used to compare the differences 
in molecular factor levels between the clinical and patho-
logical features. Cox proportional hazards analysis was used 
to evaluate the relationship between the pathological features, 
plasma molecular factor levels and overall survival. P<0.05 
was considered statistically significant.
Results
Patient characteristics and factors related to synchronous liver 
metastasis. The mean age of group B (58.8 years) was higher 
than that of group A (56.5 years), but did not reach statistical 
significance. In both groups A and B, pT3-4 occurred more 
frequently than the other stages and lymph node metastasis 
was found equally in both groups A and B (Table II). Overall 
groups A and B had statistically identical clinical features 
with the exception of lymphovascular invasion, the frequency 
of which was significantly higher in group B (p=0.004). No 
surgery-related mortality was reported in either group.
In the DV, the serum levels of VEGF (p<0.001) and 
TIMP-1 (p<0.001) in group B were significantly higher 
than those in group A. In PV, the serum levels of E-selectin 
(p=0.049), VEGF (p=0.024) and TIMP-1 (p<0.001) demon-
strated a significant difference (Table III and Fig. 1). Of note, 
the levels of VEGF and TIMP were higher in group B, whereas 
the levels of E-selectin were higher in group A.
Multivariate analyses were performed to identify clinico-
pathological factors and molecular markers associated with 
liver metastasis. The level of TIMP-1 from the DV was found 
Table III. Analyses of the levels of molecular markers in tumor drainage and peripheral veins.
 Group A Group B
 ------------------------------------------------------------------------------ -------------------------------------------------------------------------------
Markers Value Pa Value  Pa Pb
CEA PV 45.15±32.19 <0.001 116.70±100.31 <0.001 0.116
 DV 135.46±91.31  350.11±189.12  0.057
E-selectin PV 41.54±19.38 0.009 20.38± 12.01 0.280 0.049
 DV 24.37±10.01  21.16±13.45  0.311
Osteopontin PV 27.21±27.12 0.344 50.17±40.70 0.102 0.068
 DV 25.44±18.48  31.24±19.78  0.528
VEGF PV 258.80±179.33 0.471 459.15±319.82 0.529 0.024
 DV 246.58±134.29  454.17±184.18  <0.001
HGF PV 891.87±712.39 0.367 1015.1±921.63 0.303 0.266
 DV 748.91±532.47  805.69±591.17  0.338
MMP-7 PV 3.90±1.17 0.059 4.88±2.61 0.075 0.229
 DV 4.63±1.21  5.15±2.04  0.517
TIMP-1 PV 74.05±31.42 0.194 233.71±97.71 0.010 <0.001
 DV 101.9±87.27  194.01±90.73  <0.001
Values are shown as the median ± SEM; aP, comparison between DV and PV; bP, comparison between groups A and B; CEA, carcinoembryonic 
antigen; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; MMP-7, matrix metalloproteinase-7; TIMP-1, tissue 
inhibitor of metalloproteinase-1; LM, liver metastasis; PV, the serum level of a molecule from the peripheral blood; DV, the serum level 
of a molecule from the drainage vein. Units are: ng/ml for CEA, E-selectin, osteopontin, MMP-7 and TIMP-1; pg/ml for HGF and VEGF. 
PV, peripheral vein; DV, drainage vein.
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to be the most significantly different factor between groups A 
and B (HR 4.20; p=0.001) followed by the level of VEGF from 
DV (HR 4.87; p=0.004). The levels of TIMP-1 from both the 
DV and the PV were significantly different between groups A 
and B (Table IV). No clinical factors were found to be signifi-
cant in the multivariate analysis.
Factors associated with metachronous liver metastasis. The 
median follow-up period for group A was 54 months (range, 
33-78) and the 5-year disease-free and overall survival rates 
were 64.1 and 77.4%, respectively. Of the 37 patients in 
group A, 4 patients developed local recurrence, 10 developed 
systemic recurrence and 3 developed both local and systemic 
recurrence simultaneously. Of the 13 patients who had systemic 
recurrence, 10 patients (27.0%) had metachronous liver 
metastasis. The median time to recurrence was 27.3 months. 
We investigated factors correlated with metachronous liver 
metastasis by univariate and multivariate analyses (Table V), 
which revealed that only the levels of VEGF and TIMP-1 
from DV were found to be independent prognostic factors for 
metachronous liver metastasis.
Factors associated with hepatic recurrence following the 
simultaneous resection of colon cancer and synchronous 
liver metastasis. In group B, 7 patients had a solitary lesion 
and the remaining 26 patients had multiple lesions. The 
median follow-up period was 45 months (range, 27-69). The 
5-year disease-free and overall survival rates were 19.2 and 
36.8%, respectively. A total of 27 patients had recurrence 
following their initial surgery, among which 20 patients 
(60.6%) developed intrahepatic recurrence. Eight patients 
had liver-only recurrence and 12 patients had liver and other 
organ metastasis simultaneously. The median time to recur-
rence was 19 months. For adjuvant chemotherapy following 
initial surgery, 25 patients received FOLFOX, 1 FOLFOX + 
bevacizumab, 6 FOLFIRI, and 1 FOLFIRI + cetuximab. We 
performed univariate and multivariate analyses for factors 
associated with intrahepatic recurrence. A significant correla-
tion was found between the levels of VEGF from the DV and 




Figure 1. (A) Bar chart of serum levels of MMP-7, E-selectin and osteo-
pontin. (B) Bar chart of serum levels of VEGF and HGF. (C) Bar chart of 
serum levels of CEA and TIMP-1. Numbers in rectangles are the P-values.
Table IV. Multivariate analysis for factors significantly associ-
ated with the presence of liver metastasis.
Factors HR 95% CI P
Depth of invasion 2.01 0.35-5.83 0.83
(pT2 vs. pT3-4)
Lymph node metastasis 3.42 0.44-7.21 0.35
Lymphovascular invasion 2.51 0.87-6.33 0.093
Histological grade 1.74 0.18-4.00 0.88
(G1-2 vs. G3-4)
E-selectin (PV) (high vs. low) 0.61 0.25-1.94 0.078
VEGF (PV) (high vs. low) 4.32 0.97-29.07 0.054
VEGF (DV) (high vs. low) 4.87 2.07-34.41 0.004
TIMP-1 (PV) (high vs. low) 3.15 1.66-17.86 0.017
TIMP-1 (DV) (high vs. low) 4.20 1.94-22.73 0.001
VEGF, vascular endothelial growth factor; TIMP-1, tissue inhibitor 
of metalloproteinase-1; high vs. low, above the median vs. the median 
or below; PV, the serum level of a molecule from the peripheral 
blood; DV, the serum level of a molecule from the drainage vein; 
CI, confidence interval.
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Prognostic factors following liver resection. In group A, 
10 patients developed metachronous liver metastasis, of which 
7 patients received surgical resection or radiofrequency abla-
tion (RFA). In group B, 33 patients developed synchronous 
liver metastasis, and the prognosis following resection of 
liver metastasis was analyzed. The median follow-up period 
was 18 months. The 5-year disease-free and overall survival 
rates for groups A and B were 15.9 and 33.2%, respectively. 
Of 7 patients from group A who had received surgical resec-
tion or RFA with recurrence, four had solitary lesions and the 
other three had multiple lesions. All 7 patients had recurrence 
following liver resection. Five patients had hepatic-only recur-
rence and the remaining 2 had other systemic recurrences in 
lung and paraaortic lymph nodes.
Table V. Univariate and multivariate analyses for prognostic factors (metachronous liver metastasis) in group A.
 Univariate analysis Multivariate analysis
  -----------------------------------------------------------------------------------------------------------
Factors P P HR (95% CI)
pT2 vs. pT3-4  0.209 0.567 2.03 (0.212-24.011)
pN0 vs. pN1-2 0.028 0.176 24.41 (0.039-72.029)
LVI (+ vs. -) 0.433 0.629 10.42 (0.486-48.001)
Disease-free interval (<1 yr vs. >1 yr) 0.040 0.133 15.76 (0.203-62.761)
Adjuvant CTx (yes vs. no) 0.108 0.872 24.03 (0.739-104.321)
CEA (PV) 0.107 0.239 5.11 (0.623-31.340)
CEA (DV) 0.032 0.118 7.32 (0.845-27.328)
VEGF (PV) 0.059 0.200 6.09 (0.742-25.823)
VEGF (DV) <0.001 0.002 6.21 (1.241-30.048)
TIMP-1 (PV) 0.013 0.056 3.12 (0.893-18.295)
TIMP-1 (DV) 0.008 0.048 4.01 (1.003-20.180)
CEA, carcinoembryonic antigen; VEGF, vascular endothelial growth factor; TIMP-1, tissue inhibitor of metalloproteinase-1; LVI, lympho-
vascular invasion; PV, the serum level of a molecule from the peripheral blood; DV, the serum level of a molecule from the drainage vein; 
CI, confidence interval.
Table VI. Univariate and multivariate analyses for prognostic factors (intrahepatic recurrence) in group B.
 Univariate analysis Multivariate analysis
  -----------------------------------------------------------------------------------------------------------
Factors P P HR (95% CI)
pT2 vs. pT3-4  0.809 0.991 12.03 (0.011-62.074)
pN0 vs. pN1-2 0.337 0.728 9.84 (0.339-73.279)
LVI (+ vs. -) 0.043 0.278 5.20 (0.641-28.311)
Disease-free interval (<1 yr vs. >1 yr) 0.038 0.055 8.06 (0.403-37.461)
Postop. CTx. 0.847 0.895 33.92 (0.123-100.419)
(oxaliplatin vs. irinotecan)
Use of biological 0.764 0.925 40.34 (0.250-193.004)
agents (yes vs. no)
CEA (PV) 0.711 0.886 35.61 (0.213-119.407)
CEA (DV) 0.099 0.280 17.32 (0.801-47.822)
E-selectin (PV) 0.069 0.374 9.07 (0.724-36.770)
E-selectin (DV) 0.040 0.195 9.72 (0.857-40.226)
VEGF (PV) 0.055 0.252 16.09 (0.472-52.238)
VEGF (DV) <0.001 <0.001 12.16 (1.431-58.348)
TIMP-1 (PV) 0.009 0.042 8.12 (1.983-60.924)
TIMP-1 (DV) <0.001 0.026 7.40 (1.020-28.653)
CEA, carcinoembryonic antigen; VEGF, vascular endothelial growth factor; TIMP-1, tissue inhibitor of metalloproteinase-1; LVI, lympho-
vascular invasion; PV, the serum level of a molecule from the peripheral blood; DV, the serum level of a molecule from the drainage vein; 
CI, confidence interval.
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Results of the univariate and multivariate analyses of prog-
nostic factors revealed that the levels of VEGF and TIMP-1 
from DV as well as the presence of lymph node metastasis 
from the primary tumor, synchronous metastasis and R1 
resection were significantly correlated with worse prognosis 
(Table VII and Fig. 2).
Discussion
Findings of the present study have shown that the levels of VEGF 
and TIMP-1, detected in the blood from the vein that directly 
drains from the primary tumor, were correlated with synchro-
nous and metachronous liver metastasis and hepatic recurrence 
following R0 resection of liver metastasis more significantly 
than any other clinical parameters. VEGF is a well-known 
angiogenic molecule that is overexpressed in the majority of 
solid organ cancers. It is known to act specifically on endothelial 
cells to promote new vessel formation and is uniformly reported 
to be associated with cancer progression (8,9). TIMP-1 is the 
primary inhibitor of MMP-9 and an imbalance in the MMP-9/
TIMP-1 ratio has been proposed to be a potential reason for 
progression of adenoma to carcinoma (10). Several studies have 
shown that TIMP-1 level was increased in colon cancer patients 
and correlated with poor prognosis (10,11).
Table VII. Univariate and multivariate analyses for prognostic factor (disease-free survival) after resection of liver metastasis.
 Univariate analysis Multivariate analysis
 ---------------------------------------------------------------------------------------------------------------
Factors P P HR (95% CI)
pT2 vs. pT3-4 0.632 0.811 10.22 (0.421-87.447)
pN0 vs. pN1-2 <0.001 0.012 3.44 (1.003-17.019)
LVI (+ vs. -) 0.043 0.398 8.90 (0.422-19.882)
Synchronous vs. metachronous <0.001 0.003 5.61 (1.411-24.376)
Postop. CTx. (yes vs. no) 0.729 0.995 26.43 (0.092-112.921)
Solitary vs. multiple metastasis 0.037 0.123 20.540 (0.807-89.424)
R0 vs. R1 <0.001 0.003 15.001 (1.596-102.531)
CEA (PV) 0.612 0.808 54.72 (0.093-341.740)
CEA (DV) 0.211 0.420 32.75 (0.059-199.094)
E-selectin (PV) 0.091 0.284 18.78 (0.124-72.810)
E-selectin (DV) 0.100 0.282 23.04 (0.097-152.376)
VEGF (PV) 0.067 0.142 37.09 (0.852-212.52)
VEGF (DV) <0.001 <0.001 20.72 (1.781-152.377)
TIMP-1 (PV) 0.044 0.101 12.12 (0.512-243.029)
TIMP-1 (DV) <0.001 <0.001 11.35 (1.110-57.442)
CEA, carcinoembryonic antigen; VEGF, vascular endothelial growth factor; TIMP-1, tissue inhibitor of metalloproteinase-1; LVI, lymphovas-
cular invasion; PV, the serum level of a molecule from the peripheral blood; DV, the serum level of a molecule from the drainage vein.
  A   B
Figure 2. Disease-free survival curves according to the levels of (A) VEGF and (B) TIMP-1.
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To the best of our knowledge, this may be the first study 
to address the clinical importance of molecular levels from 
the tumor drainage vein (DV), rather than the peripheral vein 
(PV) in liver metastasis. The rationale behind this finding is 
that molecules that are expressed and secreted by the primary 
tumor circulate through the capillaries of the liver, lungs and 
the rest of the body prior to reaching the peripheral veins and 
during that circulation a large part of the molecules may be 
metabolized or decayed. Our hypothesis was that the level of 
these molecules detected in the DV might carry more accurate 
information regarding the tumor status and prognosis than 
in the PV. Tien et al (12) analyzed the relationship between 
the level of angiogenic factors in both the DV and the PV and 
prognosis in colon cancer patients. These authors found that 
the level of VEGF in the DV was an independent prognostic 
factor. Results of the present study are in concordance with 
those of Tien et al (12).
A previous study by Yoon et al (9) successfully demon-
strated the clinical implication of angiogenic molecular markers 
in colon cancer patients with liver metastasis. These authors 
measured the circulating levels of angiogenic molecules such 
as VEGF, bFGF, EGF and HGF preoperatively and on the third 
day, first and third month postoperatively. They also found 
that the preoperative VEGF and HGF levels were significant 
prognostic factors for recurrence-free survival. High levels 
of either of these molecular markers were prognostic of poor 
survival. The fact that a high VEGF level was correlated with 
poor prognosis is in concordance with our results, whereas the 
VEGF level found in the study by Yoon et al (9) was measured 
only in the peripheral vein. In our study, univariate analysis 
revealed that the VEGF level from both the tumor drainage 
vein and peripheral vein were significantly correlated with the 
prognosis. However, multivariate analysis revealed that the 
VEGF level from only the tumor drainage vein was an indepen-
dently significant prognostic factor. This might result from the 
fact that the peripheral VEGF level was significantly influenced 
by the tumor drainage vein VEGF level. However, the correla-
tion between peripheral and tumor drainage vein VEGF levels 
remains to be determined, as well as whether we can predict 
VEGF level in the tumor drainage vein from that in the periph-
eral vein, which is a crucial issue in terms of clinical practice.
This study has limitations. Although carried out prospec-
tively, only a small number of patients were enrolled. The 
ELISA technique for the detection of circulating molecular 
marker is the gold standard. However, the paradigm has 
now shifted in such a way that biological processes are not 
expected to be explicated through the investigation of indi-
vidual molecules. Rather it is the complex interplay between 
molecules as addressed by high-throughput technologies that 
is expected to yield complex results. Although we found that 
the VEGF and TIMP-1 levels in the tumor drainage vein have 
a significant relationship with synchronous and metachronous 
liver metastasis and hepatic recurrence following liver resec-
tion more than any other clinical parameters, blood from the 
tumor drainage vein is difficult to obtain, especially in non-
surgical patients.
Nonetheless, despite its limitations, the strong point of this 
study might be the well-defined homogenous patient subsets 
and long-term follow-up results. This study may also be one 
of few to cover not only clinical parameters but also molecular 
markers in developing predictive/prognostic factors for colon 
cancer liver metastasis.
In conclusion, on the basis of the results from the current 
study, colon cancer patients who had a high level of VEGF and 
TIMP-1 detected from the tumor drainage vein at their initial 
surgery were found to have a high risk of metachronous liver 
metastasis and hepatic recurrence following the resection of 
synchronous liver metastasis. The high levels of VEGF and 
TIMP-1 were also found to be significant prognostic factors 
that predict poor prognosis following liver resection. These 
results require validation but may pave the way for future 
transitional or clinical studies that may further elucidate colon 
cancer liver metastasis.
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